- Home
- CUE vs DTIL Comparison
CUE vs DTIL Comparison
Compare CUE & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- DTIL
- Stock Information
- Founded
- CUE 2014
- DTIL 2006
- Country
- CUE United States
- DTIL United States
- Employees
- CUE N/A
- DTIL N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- DTIL Biotechnology: Pharmaceutical Preparations
- Sector
- CUE Health Care
- DTIL Health Care
- Exchange
- CUE Nasdaq
- DTIL Nasdaq
- Market Cap
- CUE 58.9M
- DTIL 56.2M
- IPO Year
- CUE 2018
- DTIL 2019
- Fundamental
- Price
- CUE $0.78
- DTIL $5.13
- Analyst Decision
- CUE Strong Buy
- DTIL Strong Buy
- Analyst Count
- CUE 3
- DTIL 2
- Target Price
- CUE $3.00
- DTIL $47.00
- AVG Volume (30 Days)
- CUE 158.3K
- DTIL 155.2K
- Earning Date
- CUE 05-20-2025
- DTIL 05-15-2025
- Dividend Yield
- CUE N/A
- DTIL N/A
- EPS Growth
- CUE N/A
- DTIL N/A
- EPS
- CUE N/A
- DTIL 1.04
- Revenue
- CUE $9,287,000.00
- DTIL $68,696,000.00
- Revenue This Year
- CUE N/A
- DTIL N/A
- Revenue Next Year
- CUE $25.99
- DTIL $30.20
- P/E Ratio
- CUE N/A
- DTIL $4.93
- Revenue Growth
- CUE 69.16
- DTIL 40.98
- 52 Week Low
- CUE $0.45
- DTIL $3.61
- 52 Week High
- CUE $2.26
- DTIL $13.44
- Technical
- Relative Strength Index (RSI)
- CUE 46.03
- DTIL 48.80
- Support Level
- CUE $0.71
- DTIL $5.00
- Resistance Level
- CUE $0.78
- DTIL $5.97
- Average True Range (ATR)
- CUE 0.06
- DTIL 0.36
- MACD
- CUE 0.01
- DTIL -0.03
- Stochastic Oscillator
- CUE 46.11
- DTIL 13.40
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.